Cargando…

Benefit Assessment and Reimbursement of Digital Health Applications: Concepts for Setting Up a New System for Public Coverage

In Germany, some digital health applications (DiHA) became reimbursable through the statutory health insurance system with the adoption of the Digital Healthcare Act in 2019. Approaches and concepts for the German care context were developed in an iterative process, based on existing concepts from i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lantzsch, Hendrikje, Panteli, Dimitra, Martino, Filippo, Stephani, Victor, Seißler, David, Püschel, Constanze, Knöppler, Karsten, Busse, Reinhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068958/ https://www.ncbi.nlm.nih.gov/pubmed/35530738 http://dx.doi.org/10.3389/fpubh.2022.832870

Ejemplares similares

Digital Health Applications (DiHA): Approaches to develop a reimbursement process for the statutory health insurance in Austria
por: Goetz, Gregor, et al.
Publicado: (2023)

Digital health applications and the fast-track pathway to public health coverage in Germany: challenges and opportunities based on first results
por: Lantzsch, Hendrikje, et al.
Publicado: (2022)

Correction: Digital health applications and the fast-track pathway to public health coverage in Germany: challenges and opportunities based on first results
por: Lantzsch, Hendrikje, et al.
Publicado: (2023)

Reimbursement decisions for medical services in Austria: an analysis of influencing factors for the hospital individual services catalogue between 2008 and 2020
por: Goetz, Gregor, et al.
Publicado: (2022)

From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries
por: Panteli, Dimitra, et al.
Publicado: (2015)

Implementation of innovative medical technologies in German inpatient care: patterns of utilization and evidence development
por: Dreger, Marie, et al.
Publicado: (2021)

Correction to: Implementation of innovative medical technologies in German inpatient care: patterns of utilization and evidence development
por: Dreger, Marie, et al.
Publicado: (2022)

Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward
por: Panteli, Dimitra, et al.
Publicado: (2016)

Utilization of innovative medical technologies in German inpatient care: does evidence matter?
por: Eckhardt, Helene, et al.
Publicado: (2023)

Health Benefits of Air Quality Improvement: Empirical Research Based on Medical Insurance Reimbursement Data
por: Li, Ding, et al.
Publicado: (2022)

Applying a data-driven population segmentation approach in German claims data
por: Pioch, Carolina, et al.
Publicado: (2023)

Pre-reimbursement: early assessment for coverage decisions
por: Grössmann, Nicole, et al.
Publicado: (2019)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals
por: Carlson, Josh, et al.
Publicado: (2009)

Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure
por: Vogler, Sabine, et al.
Publicado: (2021)

The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
por: Tsai, Hsin-Yi, et al.
Publicado: (2022)

Appendectomy and diagnosis-related groups (DRGs): patient classification and hospital reimbursement in 11 European countries
por: Quentin, Wilm, et al.
Publicado: (2011)

Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska
por: Petrusic, Tamara, et al.
Publicado: (2015)

The Linkages Between Reimbursement and Prevention: A Mixed-Methods Approach
por: Zwaagstra Salvado, Ellen, et al.
Publicado: (2021)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

Portable continuous wave Doppler ultrasound for primary healthcare in South Africa: can the EUnetHTA Core Model guide evaluation before technology adoption?
por: Mueller, Debjani, et al.
Publicado: (2021)

Reimbursement of Digital Therapeutics: Future Perspectives in Korea
por: Ju, Jin Han, et al.
Publicado: (2022)

Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia
por: Wasir, Riswandy, et al.
Publicado: (2019)

Acute myocardial infarction and diagnosis-related groups: patient classification and hospital reimbursement in 11 European countries
por: Quentin, Wilm, et al.
Publicado: (2013)

Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States
por: Vogler, Sabine, et al.
Publicado: (2011)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023)

Media Coverage of the Benefits and Harms of Testing the Healthy: a protocol for a descriptive study
por: O'Keeffe, Mary, et al.
Publicado: (2019)

Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
por: Ling, Kexin, et al.
Publicado: (2022)

Impact of a Restriction in Reimbursement on Proton Pump Inhibitors in Patients with an Increased Risk of Gastric Complications
por: Flinterman, Linda E., et al.
Publicado: (2018)

A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries
por: Czech, Marcin, et al.
Publicado: (2020)

Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
por: Lee, SungKyung, et al.
Publicado: (2023)

A country-level analysis comparing hospital capacity and utilisation during the first COVID-19 wave across Europe()
por: Berger, Elke, et al.
Publicado: (2022)

Health care patterns and policies in 18 European countries during the first wave of the COVID-19 pandemic: an observational study
por: Panteli, Dimitra, et al.
Publicado: (2022)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Editorial: Role of health economic data in policy making and reimbursement of new medical technologies, Volume II
por: Jakovljevic, Mihajlo, et al.
Publicado: (2023)

The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
por: Scheijmans, Féline E. V., et al.
Publicado: (2022)

For-Profit Hospitals Have Thrived Because of Generous Public Reimbursement Schemes, Not Greater Efficiency: A Multi-Country Case Study
por: Jeurissen, Patrick P. T., et al.
Publicado: (2020)

How Can Digital Health Technologies Contribute to Sustainable Attainment of Universal Health Coverage in Africa? A Perspective
por: Olu, Olushayo, et al.
Publicado: (2019)

Examining the association between oncology drug clinical benefit and the time to public reimbursement
por: Thomson, Sasha, et al.
Publicado: (2021)

AMCP Partnership Forum: What’s Next for Specialty Medication Benefit Design and Reimbursement
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c0sin2flsp63c5kgon5s9eb93g